Boundless Bio
BOLDNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $2.45 Prior regular-session close from the quote source.
- $2.39–$2.46 Regular-session low and high so far today.
- 10.8K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $0.96–$3.16 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own BOLD if its ecDNA-directed cancer thesis translates into convincing human clinical data before financing needs force punitive dilution.
BOLD price history
Loading recent earnings…
Investment thesis
What must happen next
The core value driver is that Boundless Bio’s differentiated oncology biology must translate into a human efficacy and safety signal strong enough to make the platform fundable.HoldingMateriality: High
FY2025 GAAP annual operating income was -$63.552 million, showing the company is still primarily funding R&D rather than generating commercial returns. If this holds, the company can become an asset-value story; if it breaks, the equity is mostly a cash-burn vehicle.
Watch: Boundless Bio’s own clinical studies fail to show a usable efficacy or safety window in the intended cancer populations.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual operating income was -$63.552 million, showing the company is still primarily funding R&D rather than generating commercial.
Open source ↗The company must keep burn low enough to reach value-inflecting clinical milestones before its financing leverage shifts from management to new capital providers.HoldingMateriality: High
FY2025 GAAP annual operating cash flow was -$46.661 million, an improvement from -$60.841 million in FY2024. Better burn control preserves upside for existing holders; a funding gap can make even promising science a poor stock.
Watch: Trial expansion, manufacturing work, or safety follow-up increases cash burn before meaningful data arrive.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual operating cash flow was -$46.661 million, an improvement from -$60.841 million in FY2024.
Open source ↗Boundless Bio needs to maintain enough balance-sheet flexibility that clinical decisions are made for asset value rather than creditor pressure or emergency financing.HoldingMateriality: Medium
FY2025 stockholders’ equity was positive at $98.654 million. A flexible balance sheet lets the company wait for data; a stressed balance sheet can force dilution, asset sales, or trial cuts at the worst time.
Watch: New debt or convertible financing introduces restrictive covenants or senior claims on pipeline value.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 stockholders’ equity was positive at $98.654 million.
Open source ↗The focused operating model can create capital efficiency only if the small organization manages clinical, regulatory, and vendor execution without losing key talent.HoldingMateriality: Medium
The company reported 28 full-time employees as of March 8, 2026. A lean team can stretch capital, but execution failure or key-person loss would delay data and increase dilution risk.
Watch: Departure of senior scientific, clinical, regulatory, or executive leadership disrupts trial execution.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company reported 28 full-time employees as of March 8, 2026.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The core value driver is that Boundless Bio’s differentiated oncology biology must translate into a human efficacy and safety signal strong enough to make the platform fundable. If this holds, the company can become an asset-value story; if it breaks, the equity is mostly a cash-burn vehicle.
The company must keep burn low enough to reach value-inflecting clinical milestones before its financing leverage shifts from management to new capital providers. Better burn control preserves upside for existing holders; a funding gap can make even promising science a poor stock.
Boundless Bio needs to maintain enough balance-sheet flexibility that clinical decisions are made for asset value rather than creditor pressure or emergency financing. A flexible balance sheet lets the company wait for data; a stressed balance sheet can force dilution, asset sales, or trial cuts at the worst time.
The focused operating model can create capital efficiency only if the small organization manages clinical, regulatory, and vendor execution without losing key talent. A lean team can stretch capital, but execution failure or key-person loss would delay data and increase dilution risk.
All standing thesis claims
Original report summary
its ecDNA-directed cancer thesis translates into convincing human clinical data before financing needs force punitive dilution.
Bull case and bear case
Bull case and bear case for Boundless Bio
Where the evidence on Boundless Bio stands: Holding on the latest evidence (Nov 9, 2026). Of its 4 thesis points, 4 holding.
Bull case: what the evidence supports
The core value driver is that Boundless Bio’s differentiated oncology biology must translate into a human efficacy and safety signal strong enough to make the platform fundable.
The company must keep burn low enough to reach value-inflecting clinical milestones before its financing leverage shifts from management to new capital providers.
Boundless Bio needs to maintain enough balance-sheet flexibility that clinical decisions are made for asset value rather than creditor pressure or emergency financing.
The focused operating model can create capital efficiency only if the small organization manages clinical, regulatory, and vendor execution without losing key talent.
Bear case: what would count against it
Boundless Bio’s own clinical studies fail to show a usable efficacy or safety window in the intended cancer populations.
Trial expansion, manufacturing work, or safety follow-up increases cash burn before meaningful data arrive.
New debt or convertible financing introduces restrictive covenants or senior claims on pipeline value.
Thesis-Break Engine
Thesis-break watch · Boundless Bio
Loading the break-condition record for Boundless Bio.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Boundless Bio filed an SEC 8-K on 2026-08-28: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedChange in control of registrant.
Boundless Bio filed an SEC 8-K on 2026-06-23: Change in control of registrant. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Boundless Bio filed an SEC 8-K on 2026-05-08: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Boundless Bio’s own clinical studies fail to show a usable efficacy or safety window in the intended cancer populations.
- Trial expansion, manufacturing work, or safety follow-up increases cash burn before meaningful data arrive.
- New debt or convertible financing introduces restrictive covenants or senior claims on pipeline value.
- Departure of senior scientific, clinical, regulatory, or executive leadership disrupts trial execution.
BOLD news
Loading headlines…
Financial statements
BOLD income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.